Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...
MedPage Today on MSN
Gentler Regimen for HER2+ Breast Cancer Gets Good Grades in 5-Year Report
After neoadjuvant therapy, ctDNA clearance occurred in 96% of patients ...
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer Neoadjuvant approaches ...
Neoadjuvant treatment with disitamab vedotin monotherapy in patients with HER2-overexpressing muscle invasive bladder cancer (MIBC): An open-label, single-arm, phase II study. This is an ASCO Meeting ...
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRDSALT LAKE CITY, June 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results